Targeting translation initiation in breast cancer

References

• American Cancer Society. Cancer Facts and Figures 2013. Atlanta, GA: American Cancer Society, 2013.
   Google Scholar
• Meric F, Hunt KK. Translation initiation in cancer: a novel target for therapy. Mol Cancer Ther 2002; 1:971 - 9; PMID: 12481419
   PubMed Web of Science ®Google Scholar
• Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010; 10:254 - 66; http://dx.doi.org/10.1038/nrc2824; PMID: 20332778
   PubMed Web of Science ®Google Scholar
• Grzmil M, Hemmings BA. Translation regulation as a therapeutic target in cancer. Cancer Res 2012; 72:3891 - 900; http://dx.doi.org/10.1158/0008-5472.CAN-12-0026; PMID: 22850420
   PubMed Web of Science ®Google Scholar
• Malina A, Cencic R, Pelletier J. Targeting translation dependence in cancer. Oncotarget 2011; 2:76 - 88; PMID: 21378410
   PubMed Web of Science ®Google Scholar
• Ruggero D. Translational control in cancer etiology. Cold Spring Harb Perspect Biol 2013; 5:5; http://dx.doi.org/10.1101/cshperspect.a012336; PMID: 22767671
   PubMedGoogle Scholar
• Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009; 136:731 - 45; http://dx.doi.org/10.1016/j.cell.2009.01.042; PMID: 19239892
   PubMed Web of Science ®Google Scholar
• Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999; 68:913 - 63; http://dx.doi.org/10.1146/annurev.biochem.68.1.913; PMID: 10872469
   PubMed Web of Science ®Google Scholar
• Blagden SP, Willis AE. The biological and therapeutic relevance of mRNA translation in cancer. Nat Rev Clin Oncol 2011; 8:280 - 91; http://dx.doi.org/10.1038/nrclinonc.2011.16; PMID: 21364523
   PubMed Web of Science ®Google Scholar
• Aitken CE, Lorsch JR. A mechanistic overview of translation initiation in eukaryotes. Nat Struct Mol Biol 2012; 19:568 - 76; http://dx.doi.org/10.1038/nsmb.2303; PMID: 22664984
   PubMed Web of Science ®Google Scholar
• Wells SE, Hillner PE, Vale RD, Sachs AB. Circularization of mRNA by eukaryotic translation initiation factors. Mol Cell 1998; 2:135 - 40; http://dx.doi.org/10.1016/S1097-2765(00)80122-7; PMID: 9702200
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27:2278 - 87; http://dx.doi.org/10.1200/JCO.2008.20.0766; PMID: 19332717
   PubMed Web of Science ®Google Scholar
• Hsieh AC, Truitt ML, Ruggero D. Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer 2011; 105:329 - 36; http://dx.doi.org/10.1038/bjc.2011.241; PMID: 21772331
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F. Translation initiation factor 4E (eIF4E): prognostic marker and potential therapeutic target. Ann Surg Oncol 2008; 15:2996 - 7; http://dx.doi.org/10.1245/s10434-008-0116-7; PMID: 18712446
   PubMed Web of Science ®Google Scholar
• Li BD, McDonald JC, Nassar R, De Benedetti A. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg 1998; 227:756-6l; discussion 61-3.
   Google Scholar
• Dever TE, Green R. The elongation, termination, and recycling phases of translation in eukaryotes. Cold Spring Harb Perspect Biol 2012; 4:a013706; http://dx.doi.org/10.1101/cshperspect.a013706; PMID: 22751155
   PubMed Web of Science ®Google Scholar
• Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006; 314:467 - 71; http://dx.doi.org/10.1126/science.1130276; PMID: 17053147
   PubMed Web of Science ®Google Scholar
• Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 2001; 20:4370 - 9; http://dx.doi.org/10.1093/emboj/20.16.4370; PMID: 11500364
   PubMed Web of Science ®Google Scholar
• Ferrari S, Bandi HR, Hofsteenge J, Bussian BM, Thomas G. Mitogen-activated 70K S6 kinase. Identification of in vitro 40 S ribosomal S6 phosphorylation sites. J Biol Chem 1991; 266:22770 - 5; PMID: 1939282
   PubMed Web of Science ®Google Scholar
• Yamnik RL, Holz MK. mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Lett 2010; 584:124 - 8; http://dx.doi.org/10.1016/j.febslet.2009.11.041; PMID: 19925796
   PubMed Web of Science ®Google Scholar
• Holcik M, Sonenberg N, Korneluk RG. Internal ribosome initiation of translation and the control of cell death. Trends Genet 2000; 16:469 - 73; http://dx.doi.org/10.1016/S0168-9525(00)02106-5; PMID: 11050335
   PubMed Web of Science ®Google Scholar
• Sherrill KW, Byrd MP, Van Eden ME, Lloyd RE. BCL-2 translation is mediated via internal ribosome entry during cell stress. J Biol Chem 2004; 279:29066 - 74; http://dx.doi.org/10.1074/jbc.M402727200; PMID: 15123638
   PubMed Web of Science ®Google Scholar
• Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A, Willis AE, Roy DC, Caligiuri MA, Marcucci G, et al. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 2006; 107:2507 - 16; http://dx.doi.org/10.1182/blood-2005-09-3732; PMID: 16293596
   PubMed Web of Science ®Google Scholar
• Lang KJ, Kappel A, Goodall GJ. Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell 2002; 13:1792 - 801; http://dx.doi.org/10.1091/mbc.02-02-0017; PMID: 12006670
   PubMed Web of Science ®Google Scholar
• Miller DL, Dibbens JA, Damert A, Risau W, Vadas MA, Goodall GJ. The vascular endothelial growth factor mRNA contains an internal ribosome entry site. FEBS Lett 1998; 434:417 - 20; http://dx.doi.org/10.1016/S0014-5793(98)01025-4; PMID: 9742966
   PubMed Web of Science ®Google Scholar
• Holcik M, Yeh C, Korneluk RG, Chow T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 2000; 19:4174 - 7; http://dx.doi.org/10.1038/sj.onc.1203765; PMID: 10962579
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, Hortobagyi GN, Mills GB, Gonzalez-Angulo AM. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res 2012; 14:R138; http://dx.doi.org/10.1186/bcr3343; PMID: 23102376
   PubMedGoogle Scholar
• Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010; 120:2406 - 13; http://dx.doi.org/10.1172/JCI41680; PMID: 20530877
   PubMed Web of Science ®Google Scholar
• Zhang L, Pan X, Hershey JW. Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J Biol Chem 2007; 282:5790 - 800; http://dx.doi.org/10.1074/jbc.M606284200; PMID: 17170115
   PubMed Web of Science ®Google Scholar
• Bachmann F, Bänziger R, Burger MM. Cloning of a novel protein overexpressed in human mammary carcinoma. Cancer Res 1997; 57:988 - 94; PMID: 9041205
   PubMed Web of Science ®Google Scholar
• Yin JY, Shen J, Dong ZZ, Huang Q, Zhong MZ, Feng DY, Zhou HH, Zhang JT, Liu ZQ. Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair. Clin Cancer Res 2011; 17:4600 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-10-2591; PMID: 21610145
   PubMed Web of Science ®Google Scholar
• Dong Z, Zhang JT. EIF3 p170, a mediator of mimosine effect on protein synthesis and cell cycle progression. Mol Biol Cell 2003; 14:3942 - 51; http://dx.doi.org/10.1091/mbc.E02-12-0784; PMID: 12972576
   PubMed Web of Science ®Google Scholar
• Dong Z, Liu LH, Han B, Pincheira R, Zhang JT. Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth. Oncogene 2004; 23:3790 - 801; http://dx.doi.org/10.1038/sj.onc.1207465; PMID: 15094776
   PubMed Web of Science ®Google Scholar
• Rothe M, Ko Y, Albers P, Wernert N. Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular seminomas. Am J Pathol 2000; 157:1597 - 604; http://dx.doi.org/10.1016/S0002-9440(10)64797-9; PMID: 11073819
   PubMed Web of Science ®Google Scholar
• Scoles DR, Yong WH, Qin Y, Wawrowsky K, Pulst SM. Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c). Hum Mol Genet 2006; 15:1059 - 70; http://dx.doi.org/10.1093/hmg/ddl021; PMID: 16497727
   PubMed Web of Science ®Google Scholar
• Nupponen NN, Porkka K, Kakkola L, Tanner M, Persson K, Borg A, Isola J, Visakorpi T. Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol 1999; 154:1777 - 83; http://dx.doi.org/10.1016/S0002-9440(10)65433-8; PMID: 10362802
   PubMed Web of Science ®Google Scholar
• Shi J, Kahle A, Hershey JW, Honchak BM, Warneke JA, Leong SP, Nelson MA. Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells. Oncogene 2006; 25:4923 - 36; http://dx.doi.org/10.1038/sj.onc.1209495; PMID: 16532022
   PubMed Web of Science ®Google Scholar
• LeFebvre AK, Korneeva NL, Trutschl M, Cvek U, Duzan RD, Bradley CA, Hershey JW, Rhoads RE. Translation initiation factor eIF4G-1 binds to eIF3 through the eIF3e subunit. J Biol Chem 2006; 281:22917 - 32; http://dx.doi.org/10.1074/jbc.M605418200; PMID: 16766523
   PubMed Web of Science ®Google Scholar
• Rasmussen SB, Kordon E, Callahan R, Smith GH. Evidence for the transforming activity of a truncated Int6 gene, in vitro. Oncogene 2001; 20:5291 - 301; http://dx.doi.org/10.1038/sj.onc.1204624; PMID: 11536042
   PubMed Web of Science ®Google Scholar
• Marchetti A, Buttitta F, Pellegrini S, Bertacca G, Callahan R. Reduced expression of INT-6/eIF3-p48 in human tumors. Int J Oncol 2001; 18:175 - 9; PMID: 11115556
   PubMed Web of Science ®Google Scholar
• Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA, Jaitly N, Martens JW, Luider TM, Foekens JA, et al. Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics 2009; 8:1278 - 94; http://dx.doi.org/10.1074/mcp.M800493-MCP200; PMID: 19329653
   PubMed Web of Science ®Google Scholar
• Gillis LD, Lewis SM. Decreased eIF3e/Int6 expression causes epithelial-to-mesenchymal transition in breast epithelial cells. Oncogene 2013; 32:3598 - 605; http://dx.doi.org/10.1038/onc.2012.371; PMID: 22907435
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay A, Matsumoto T, Maitra U. Fission yeast Int6 is not essential for global translation initiation, but deletion of int6(+) causes hypersensitivity to caffeine and affects spore formation. Mol Biol Cell 2000; 11:4005 - 18; http://dx.doi.org/10.1091/mbc.11.11.4005; PMID: 11071923
   PubMed Web of Science ®Google Scholar
• Grzmil M, Rzymski T, Milani M, Harris AL, Capper RG, Saunders NJ, Salhan A, Ragoussis J, Norbury CJ. An oncogenic role of eIF3e/INT6 in human breast cancer. Oncogene 2010; 29:4080 - 9; http://dx.doi.org/10.1038/onc.2010.152; PMID: 20453879
   PubMed Web of Science ®Google Scholar
• Rozen F, Edery I, Meerovitch K, Dever TE, Merrick WC, Sonenberg N. Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A and 4F. Mol Cell Biol 1990; 10:1134 - 44; PMID: 2304461
   PubMed Web of Science ®Google Scholar
• Shuda M, Kondoh N, Tanaka K, Ryo A, Wakatsuki T, Hada A, Goseki N, Igari T, Hatsuse K, Aihara T, et al. Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. Anticancer Res 2000; 20:2489 - 94; PMID: 10953316
   PubMed Web of Science ®Google Scholar
• Eberle J, Krasagakis K, Orfanos CE. Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro. Int J Cancer 1997; 71:396 - 401; http://dx.doi.org/10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E; PMID: 9139875
   PubMed Web of Science ®Google Scholar
• Schroeder JA, Masri AA, Adriance MC, Tessier JC, Kotlarczyk KL, Thompson MC, Gendler SJ. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004; 23:5739 - 47; http://dx.doi.org/10.1038/sj.onc.1207713; PMID: 15221004
   PubMed Web of Science ®Google Scholar
• Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9:874 - 85; http://dx.doi.org/10.1038/nrc2761; PMID: 19935676
   PubMed Web of Science ®Google Scholar
• Jin C, Rajabi H, Rodrigo CM, Porco JA Jr., Kufe D. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene 2013; 32:2179 - 88; http://dx.doi.org/10.1038/onc.2012.236; PMID: 22689062
   PubMed Web of Science ®Google Scholar
• Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG, Brem B, Greger H, Lowe SW, Porco JA Jr., et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008; 118:2651 - 60; PMID: 18551192
   PubMed Web of Science ®Google Scholar
• Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 2009; 113:4656 - 66; http://dx.doi.org/10.1182/blood-2008-09-175430; PMID: 19190247
   PubMed Web of Science ®Google Scholar
• Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J, Shi W, Zhang Z, Rajasekhar VK, Pagano NC, et al. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med 2011; 208:1799 - 807; http://dx.doi.org/10.1084/jem.20110846; PMID: 21859846
   PubMed Web of Science ®Google Scholar
• Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Kimball SR, Cooper JA. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol 1999; 19:1871 - 80; PMID: 10022874
   PubMed Web of Science ®Google Scholar
• Joshi B, Cai AL, Keiper BD, Minich WB, Mendez R, Beach CM, Stepinski J, Stolarski R, Darzynkiewicz E, Rhoads RE. Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209. J Biol Chem 1995; 270:14597 - 603; http://dx.doi.org/10.1074/jbc.270.24.14597; PMID: 7782323
   PubMed Web of Science ®Google Scholar
• Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004; 5:553 - 63; http://dx.doi.org/10.1016/j.ccr.2004.05.024; PMID: 15193258
   PubMed Web of Science ®Google Scholar
• De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23:3189 - 99; http://dx.doi.org/10.1038/sj.onc.1207545; PMID: 15094768
   PubMed Web of Science ®Google Scholar
• Zimmer SG, DeBenedetti A, Graff JR. Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 2000; 20:3A 1343 - 51; PMID: 10928042
   PubMed Web of Science ®Google Scholar
• Culjkovic B, Tan K, Orolicki S, Amri A, Meloche S, Borden KL. The eIF4E RNA regulon promotes the Akt signaling pathway. J Cell Biol 2008; 181:51 - 63; http://dx.doi.org/10.1083/jcb.200707018; PMID: 18391071
   PubMed Web of Science ®Google Scholar
• Li S, Takasu T, Perlman DM, Peterson MS, Burrichter D, Avdulov S, Bitterman PB, Polunovsky VA. Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 2003; 278:3015 - 22; http://dx.doi.org/10.1074/jbc.M208821200; PMID: 12441348
   PubMed Web of Science ®Google Scholar
• Rhoads RE. Regulation of eukaryotic protein synthesis by initiation factors. J Biol Chem 1993; 268:3017 - 20; PMID: 8428975
   PubMed Web of Science ®Google Scholar
• Rosenwald IB, Kaspar R, Rousseau D, Gehrke L, Leboulch P, Chen JJ, Schmidt EV, Sonenberg N, London IM. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J Biol Chem 1995; 270:21176 - 80; http://dx.doi.org/10.1074/jbc.270.36.21176; PMID: 7673150
   PubMed Web of Science ®Google Scholar
• Bitterman PB, Polunovsky VA. Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation. Mol Cancer Ther 2012; 11:1051 - 61; http://dx.doi.org/10.1158/1535-7163.MCT-11-0530; PMID: 22572598
   PubMed Web of Science ®Google Scholar
• Feoktistova K, Tuvshintogs E, Do A, Fraser CS. Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity. Proc Natl Acad Sci U S A 2013; 110:13339 - 44; http://dx.doi.org/10.1073/pnas.1303781110; PMID: 23901100
   PubMed Web of Science ®Google Scholar
• Larsson O, Li S, Issaenko OA, Avdulov S, Peterson M, Smith K, Bitterman PB, Polunovsky VA. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res 2007; 67:6814 - 24; http://dx.doi.org/10.1158/0008-5472.CAN-07-0752; PMID: 17638893
   PubMed Web of Science ®Google Scholar
• Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, Pandolfi PP. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004; 10:484 - 6; http://dx.doi.org/10.1038/nm1042; PMID: 15098029
   PubMed Web of Science ®Google Scholar
• Zindy P, Bergé Y, Allal B, Filleron T, Pierredon S, Cammas A, Beck S, Mhamdi L, Fan L, Favre G, et al. Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. Cancer Res 2011; 71:4068 - 73; http://dx.doi.org/10.1158/0008-5472.CAN-11-0420; PMID: 21498638
   PubMed Web of Science ®Google Scholar
• Li BD, Gruner JS, Abreo F, Johnson LW, Yu H, Nawas S, McDonald JC, DeBenedetti A. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 2002; 235:732 - 8, discussion 738-9; http://dx.doi.org/10.1097/00000658-200205000-00016; PMID: 11981220
   PubMed Web of Science ®Google Scholar
• McClusky DR, Chu Q, Yu H, Debenedetti A, Johnson LW, Meschonat C, Turnage R, McDonald JC, Abreo F, Li BD. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg 2005; 242:584 - 90, discussion 590-2; PMID: 16192819
   PubMed Web of Science ®Google Scholar
• Holm N, Byrnes K, Johnson L, Abreo F, Sehon K, Alley J, Meschonat C, Md QC, Li BD. A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Negative Breast Cancer. Ann Surg Oncol 2008.
   Google Scholar
• Flowers A, Chu QD, Panu L, Meschonat C, Caldito G, Lowery-Nordberg M, Li BD. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome. Surgery 2009; 146:220 - 6; http://dx.doi.org/10.1016/j.surg.2009.05.010; PMID: 19628077
   PubMed Web of Science ®Google Scholar
• Hiller DJ, Chu Q, Meschonat C, Panu L, Burton G, Li BD. Predictive value of eIF4E reduction after neoadjuvant therapy in breast cancer. J Surg Res 2009; 156:265 - 9; http://dx.doi.org/10.1016/j.jss.2009.03.060; PMID: 19665145
   PubMed Web of Science ®Google Scholar
• Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM, Parsons SH, Brail LH, Colligan BM, Koop JW, et al. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 2009; 69:3866 - 73; http://dx.doi.org/10.1158/0008-5472.CAN-08-3472; PMID: 19383915
   PubMed Web of Science ®Google Scholar
• Coleman LJ, Peter MB, Teall TJ, Brannan RA, Hanby AM, Honarpisheh H, Shaaban AM, Smith L, Speirs V, Verghese ET, et al. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer 2009; 100:1393 - 9; http://dx.doi.org/10.1038/sj.bjc.6605044; PMID: 19367274
   PubMed Web of Science ®Google Scholar
• Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, Cangiarella J, Arju R, Formenti SC, Schneider RJ. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 2007; 28:501 - 12; http://dx.doi.org/10.1016/j.molcel.2007.10.019; PMID: 17996713
   PubMed Web of Science ®Google Scholar
• Liu J, Stevens PD, Eshleman NE, Gao T. Protein phosphatase PPM1G regulates protein translation and cell growth by dephosphorylating 4E binding protein 1 (4E-BP1). J Biol Chem 2013; 288:23225 - 33; http://dx.doi.org/10.1074/jbc.M113.492371; PMID: 23814053
   PubMed Web of Science ®Google Scholar
• Fukuchi-Shimogori T, Ishii I, Kashiwagi K, Mashiba H, Ekimoto H, Igarashi K. Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res 1997; 57:5041 - 4; PMID: 9371500
   PubMed Web of Science ®Google Scholar
• Ramírez-Valle F, Braunstein S, Zavadil J, Formenti SC, Schneider RJ. eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol 2008; 181:293 - 307; http://dx.doi.org/10.1083/jcb.200710215; PMID: 18426977
   PubMed Web of Science ®Google Scholar
• Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, Goldberg J, Hochman T, Formenti SC, Schneider RJ. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol 2009; 11:903 - 8; http://dx.doi.org/10.1038/ncb1900; PMID: 19525934
   PubMed Web of Science ®Google Scholar
• Mahoney SJ, Dempsey JM, Blenis J. Cell signaling in protein synthesis ribosome biogenesis and translation initiation and elongation. Prog Mol Biol Transl Sci 2009; 90:53 - 107; http://dx.doi.org/10.1016/S1877-1173(09)90002-3; PMID: 20374739
   PubMed Web of Science ®Google Scholar
• Wu H, Yang JM, Jin S, Zhang H, Hait WN. Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. Cancer Res 2006; 66:3015 - 23; http://dx.doi.org/10.1158/0008-5472.CAN-05-1554; PMID: 16540650
   PubMed Web of Science ®Google Scholar
• Arora S, Yang JM, Kinzy TG, Utsumi R, Okamoto T, Kitayama T, Ortiz PA, Hait WN. Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer Res 2003; 63:6894 - 9; PMID: 14583488
   PubMed Web of Science ®Google Scholar
• Alaiya AA, Franzén B, Fujioka K, Moberger B, Schedvins K, Silfversvärd C, Linder S, Auer G. Phenotypic analysis of ovarian carcinoma: polypeptide expression in benign, borderline and malignant tumors. Int J Cancer 1997; 73:678 - 83; http://dx.doi.org/10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2; PMID: 9398045
   PubMed Web of Science ®Google Scholar
• Nakamura J, Aoyagi S, Nanchi I, Nakatsuka S, Hirata E, Shibata S, Fukuda M, Yamamoto Y, Fukuda I, Tatsumi N, et al. Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle. Int J Oncol 2009; 34:1181 - 9; PMID: 19360331
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ren X, Zhang Y, Patel R, Sharma A, Wu H, Robertson GP, Yan L, Rubin E, Yang JM. eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. Cancer Res 2011; 71:2654 - 63; http://dx.doi.org/10.1158/0008-5472.CAN-10-2889; PMID: 21307130
   PubMed Web of Science ®Google Scholar
• Bagaglio DM, Cheng EH, Gorelick FS, Mitsui K, Nairn AC, Hait WN. Phosphorylation of elongation factor 2 in normal and malignant rat glial cells. Cancer Res 1993; 53:Suppl 2260 - 4; PMID: 8485712
   PubMedGoogle Scholar
• Arora S, Yang JM, Hait WN. Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase. Cancer Res 2005; 65:3806 - 10; http://dx.doi.org/10.1158/0008-5472.CAN-04-4036; PMID: 15867377
   PubMed Web of Science ®Google Scholar
• Cheng EH, Gorelick FS, Czernik AJ, Bagaglio DM, Hait WN. Calmodulin-dependent protein kinases in rat glioblastoma. Cell Growth Differ 1995; 6:615 - 21; PMID: 7647041
   PubMedGoogle Scholar
• Parmer TG, Ward MD, Yurkow EJ, Vyas VH, Kearney TJ, Hait WN. Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer. Br J Cancer 1999; 79:59 - 64; http://dx.doi.org/10.1038/sj.bjc.6690012; PMID: 10408694
   PubMed Web of Science ®Google Scholar
• Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat B. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One 2012; 7:e41171; http://dx.doi.org/10.1371/journal.pone.0041171; PMID: 22911754
   PubMedGoogle Scholar
• Wen YH, Shi X, Chiriboga L, Matsahashi S, Yee H, Afonja O. Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncol Rep 2007; 18:1387 - 93; PMID: 17982621
   PubMed Web of Science ®Google Scholar
• Yang HS, Jansen AP, Nair R, Shibahara K, Verma AK, Cmarik JL, Colburn NH. A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation. Oncogene 2001; 20:669 - 76; http://dx.doi.org/10.1038/sj.onc.1204137; PMID: 11314000
   PubMed Web of Science ®Google Scholar
• Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N, Colburn NH. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 2003; 23:26 - 37; http://dx.doi.org/10.1128/MCB.23.1.26-37.2003; PMID: 12482958
   PubMed Web of Science ®Google Scholar
• Schmid T, Jansen AP, Baker AR, Hegamyer G, Hagan JP, Colburn NH. Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion. Cancer Res 2008; 68:1254 - 60; http://dx.doi.org/10.1158/0008-5472.CAN-07-1719; PMID: 18296647
   PubMed Web of Science ®Google Scholar
• Teske BF, Baird TD, Wek RC. Methods for analyzing eIF2 kinases and translational control in the unfolded protein response. Methods Enzymol 2011; 490:333 - 56; http://dx.doi.org/10.1016/B978-0-12-385114-7.00019-2; PMID: 21266259
   PubMed Web of Science ®Google Scholar
• Backer MV, Backer JM, Chinnaiyan P. Targeting the unfolded protein response in cancer therapy. Methods Enzymol 2011; 491:37 - 56; http://dx.doi.org/10.1016/B978-0-12-385928-0.00003-1; PMID: 21329793
   PubMed Web of Science ®Google Scholar
• Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol 2012; 6:590 - 610; http://dx.doi.org/10.1016/j.molonc.2012.09.006; PMID: 23102669
   PubMed Web of Science ®Google Scholar
• Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, Bertrand E, Filipowicz W. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005; 309:1573 - 6; http://dx.doi.org/10.1126/science.1115079; PMID: 16081698
   PubMed Web of Science ®Google Scholar
• Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci U S A 2004; 101:18105 - 10; http://dx.doi.org/10.1073/pnas.0406927102; PMID: 15601771
   PubMed Web of Science ®Google Scholar
• Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, Gonzalez-Angulo A, Meric-Bernstam F. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 2008; 7:1782 - 8; http://dx.doi.org/10.1158/1535-7163.MCT-07-2357; PMID: 18644990
   PubMed Web of Science ®Google Scholar
• Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007; 117:2638 - 48; http://dx.doi.org/10.1172/JCI32044; PMID: 17786246
   PubMed Web of Science ®Google Scholar
• Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 2011; 17:6582 - 91; http://dx.doi.org/10.1158/1078-0432.CCR-11-0430; PMID: 21831956
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals I. Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel (NSCLC). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010- [cited 2014 March 27]. Available from: http://clinicaltrials.gov/ct2/show/NCT01234038 NLM identifier: NCT1234038.
   Google Scholar
• Pharmaceuticals I. Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010- [cited 2014 March 27]. Available from: http://clinicaltrials.gov/ct2/show/NCT01234025 NLM identifier: NCT01234025.
   Google Scholar
• Ghosh B, Benyumov AO, Ghosh P, Jia Y, Avdulov S, Dahlberg PS, Peterson M, Smith K, Polunovsky VA, Bitterman PB, et al. Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem Biol 2009; 4:367 - 77; http://dx.doi.org/10.1021/cb9000475; PMID: 19351181
   PubMed Web of Science ®Google Scholar
• Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH Jr., et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 2009; 114:257 - 60; http://dx.doi.org/10.1182/blood-2009-02-205153; PMID: 19433856
   PubMed Web of Science ®Google Scholar
• Borden KL. Targeting the oncogene eIF4E in cancer: From the bench to clinical trials. Clin Invest Med 2011; 34:E315; PMID: 22129918
   PubMedGoogle Scholar
• Kraljacic BC, Arguello M, Amri A, Cormack G, Borden K. Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Leukemia 2011; 25:1197 - 200; http://dx.doi.org/10.1038/leu.2011.57; PMID: 21455212
   PubMed Web of Science ®Google Scholar
• Jewish General Hospital. A Phase I/II Study of Ribavirin and Low-dose Cytarabine Arabinoside (Ara-C) in Acute Myeloid Leukemia (AML) M4 and M5 Subtypes, and AML With High eIF4E Expression. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010- [cited 2014 March 27]. Available from: http://clinicaltrials.gov/ct2/show/record/NCT01056523 NLM identifier: NCT01056523.
   Google Scholar
• Jewish General Hospital. A Phase I/II Exploratory Study of Ribavirin in Metastatic Breast Cancer Expressing Elevated eIF4E. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010- [cited 2014 March 27]. Available from: http://clinicaltrials.gov/ct2/show/NCT01056757 NLM identifier: NCT01056757.
   Google Scholar
• Westman B, Beeren L, Grudzien E, Stepinski J, Worch R, Zuberek J, Jemielity J, Stolarski R, Darzynkiewicz E, Rhoads RE, et al. The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro. RNA 2005; 11:1505 - 13; http://dx.doi.org/10.1261/rna.2132505; PMID: 16131589
   PubMed Web of Science ®Google Scholar
• Yan Y, Svitkin Y, Lee JM, Bisaillon M, Pelletier J. Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. RNA 2005; 11:1238 - 44; http://dx.doi.org/10.1261/rna.2930805; PMID: 16043507
   PubMed Web of Science ®Google Scholar
• Herbert TP, Fåhraeus R, Prescott A, Lane DP, Proud CG. Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E. Curr Biol 2000; 10:793 - 6; http://dx.doi.org/10.1016/S0960-9822(00)00567-4; PMID: 10898981
   PubMed Web of Science ®Google Scholar
• Salaün P, Boulben S, Mulner-Lorillon O, Bellé R, Sonenberg N, Morales J, Cormier P. Embryonic-stage-dependent changes in the level of eIF4E-binding proteins during early development of sea urchin embryos. J Cell Sci 2005; 118:1385 - 94; http://dx.doi.org/10.1242/jcs.01716; PMID: 15769855
   PubMed Web of Science ®Google Scholar
• Ko SY, Guo H, Barengo N, Naora H. Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E. Clin Cancer Res 2009; 15:4336 - 47; http://dx.doi.org/10.1158/1078-0432.CCR-08-2924; PMID: 19458052
   PubMed Web of Science ®Google Scholar
• Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 2007; 128:257 - 67; http://dx.doi.org/10.1016/j.cell.2006.11.046; PMID: 17254965
   PubMed Web of Science ®Google Scholar
• Cencic R, Hall DR, Robert F, Du Y, Min J, Li L, Qui M, Lewis I, Kurtkaya S, Dingledine R, et al. Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A 2011; 108:1046 - 51; http://dx.doi.org/10.1073/pnas.1011477108; PMID: 21191102
   PubMed Web of Science ®Google Scholar
• Bordeleau ME, Matthews J, Wojnar JM, Lindqvist L, Novac O, Jankowsky E, Sonenberg N, Northcote P, Teesdale-Spittle P, Pelletier J. Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc Natl Acad Sci U S A 2005; 102:10460 - 5; http://dx.doi.org/10.1073/pnas.0504249102; PMID: 16030146
   PubMed Web of Science ®Google Scholar
• Bordeleau ME, Cencic R, Lindqvist L, Oberer M, Northcote P, Wagner G, Pelletier J. RNA-mediated sequestration of the RNA helicase eIF4A by Pateamine A inhibits translation initiation. Chem Biol 2006; 13:1287 - 95; http://dx.doi.org/10.1016/j.chembiol.2006.10.005; PMID: 17185224
   PubMed Web of Science ®Google Scholar
• Kuznetsov G, Xu Q, Rudolph-Owen L, Tendyke K, Liu J, Towle M, Zhao N, Marsh J, Agoulnik S, Twine N, et al. Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Mol Cancer Ther 2009; 8:1250 - 60; http://dx.doi.org/10.1158/1535-7163.MCT-08-1026; PMID: 19417157
   PubMed Web of Science ®Google Scholar
• Cencic R, Carrier M, Galicia-Vázquez G, Bordeleau ME, Sukarieh R, Bourdeau A, Brem B, Teodoro JG, Greger H, Tremblay ML, et al. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One 2009; 4:e5223; http://dx.doi.org/10.1371/journal.pone.0005223; PMID: 19401772
   PubMed Web of Science ®Google Scholar
• Bordeleau ME, Mori A, Oberer M, Lindqvist L, Chard LS, Higa T, Belsham GJ, Wagner G, Tanaka J, Pelletier J. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat Chem Biol 2006; 2:213 - 20; http://dx.doi.org/10.1038/nchembio776; PMID: 16532013
   PubMed Web of Science ®Google Scholar
• Tsumuraya T, Ishikawa C, Machijima Y, Nakachi S, Senba M, Tanaka J, Mori N. Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem Pharmacol 2011; 81:713 - 22; http://dx.doi.org/10.1016/j.bcp.2010.12.025; PMID: 21219881
   PubMed Web of Science ®Google Scholar
• Shi XP, Yin KC, Ahern J, Davis LJ, Stern AM, Waxman L. Effects of N1-guanyl-1,7-diaminoheptane, an inhibitor of deoxyhypusine synthase, on the growth of tumorigenic cell lines in culture. Biochim Biophys Acta 1996; 1310:119 - 26; http://dx.doi.org/10.1016/0167-4889(95)00165-4; PMID: 9244184
   PubMed Web of Science ®Google Scholar
• Clement PM, Hanauske-Abel HM, Wolff EC, Kleinman HK, Park MH. The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int J Cancer 2002; 100:491 - 8; http://dx.doi.org/10.1002/ijc.10515; PMID: 12115536
   PubMed Web of Science ®Google Scholar
• Zhou H, Shen T, Luo Y, Liu L, Chen W, Xu B, Han X, Pang J, Rivera CA, Huang S. The antitumor activity of the fungicide ciclopirox. Int J Cancer 2010; 127:2467 - 77; http://dx.doi.org/10.1002/ijc.25255; PMID: 20225320
   PubMed Web of Science ®Google Scholar
• Jasiulionis MG, Luchessi AD, Moreira AG, Souza PP, Suenaga AP, Correa M, Costa CA, Curi R, Costa-Neto CM. Inhibition of eukaryotic translation initiation factor 5A (eIF5A) hypusination impairs melanoma growth. Cell Biochem Funct 2007; 25:109 - 14; http://dx.doi.org/10.1002/cbf.1351; PMID: 16850525
   PubMed Web of Science ®Google Scholar
• Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, Hurren R, Datti A, Batey RA, Wrana J, et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009; 114:3064 - 73; http://dx.doi.org/10.1182/blood-2009-03-209965; PMID: 19589922
   PubMed Web of Science ®Google Scholar
• Redpath NT, Foulstone EJ, Proud CG. Regulation of translation elongation factor-2 by insulin via a rapamycin-sensitive signalling pathway. EMBO J 1996; 15:2291 - 7; PMID: 8641294
   PubMed Web of Science ®Google Scholar
• Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 2008; 68:2934 - 43; http://dx.doi.org/10.1158/0008-5472.CAN-07-6487; PMID: 18413763
   PubMed Web of Science ®Google Scholar
• Huang MT. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 1975; 11:511 - 9; PMID: 1237080
   PubMedGoogle Scholar
• Fresno M, Jiménez A, Vázquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 1977; 72:323 - 30; http://dx.doi.org/10.1111/j.1432-1033.1977.tb11256.x; PMID: 319998
   PubMedGoogle Scholar
• Gürel G, Blaha G, Moore PB, Steitz TA. U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol 2009; 389:146 - 56; http://dx.doi.org/10.1016/j.jmb.2009.04.005; PMID: 19362093
   PubMed Web of Science ®Google Scholar
• Wetzler M, Segal D. Omacetaxine as an anticancer therapeutic: what is old is new again. Curr Pharm Des 2011; 17:59 - 64; http://dx.doi.org/10.2174/138161211795049778; PMID: 21294709
   PubMed Web of Science ®Google Scholar
• Memmott RM, Dennis PA. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal 2009; 21:656 - 64; http://dx.doi.org/10.1016/j.cellsig.2009.01.004; PMID: 19166931
   PubMed Web of Science ®Google Scholar
• Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004; 10:7031 - 42; http://dx.doi.org/10.1158/1078-0432.CCR-04-0361; PMID: 15501983
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, et al, Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271 - 81; http://dx.doi.org/10.1056/NEJMoa066838; PMID: 17538086
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, et al, RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449 - 56; http://dx.doi.org/10.1016/S0140-6736(08)61039-9; PMID: 18653228
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, et al, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:514 - 23; http://dx.doi.org/10.1056/NEJMoa1009290; PMID: 21306238
   PubMed Web of Science ®Google Scholar
• Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381:125 - 32; http://dx.doi.org/10.1016/S0140-6736(12)61134-9; PMID: 23158522
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381:817 - 24; http://dx.doi.org/10.1016/S0140-6736(12)61767-X; PMID: 23312829
   PubMed Web of Science ®Google Scholar
• Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27:4536 - 41; http://dx.doi.org/10.1200/JCO.2008.21.3033; PMID: 19687332
   PubMed Web of Science ®Google Scholar
• Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O’Reilly T, Evans DB, Chen S, Lane HA. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005; 11:5319 - 28; http://dx.doi.org/10.1158/1078-0432.CCR-04-2402; PMID: 16033851
   PubMed Web of Science ®Google Scholar
• Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012; 30:2718 - 24; http://dx.doi.org/10.1200/JCO.2011.39.0708; PMID: 22565002
   PubMed Web of Science ®Google Scholar
• Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27:2630 - 7; http://dx.doi.org/10.1200/JCO.2008.18.8391; PMID: 19380449
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520 - 9; http://dx.doi.org/10.1056/NEJMoa1109653; PMID: 22149876
   PubMed Web of Science ®Google Scholar
• Beaver JA, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 2012; 8:651 - 7; http://dx.doi.org/10.2217/fon.12.49; PMID: 22764762
   PubMed Web of Science ®Google Scholar
• Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013; 31:195 - 202; http://dx.doi.org/10.1200/JCO.2011.38.3331; PMID: 23233719
   PubMed Web of Science ®Google Scholar
• Mazzoletti M, Bortolin F, Brunelli L, Pastorelli R, Di Giandomenico S, Erba E, Ubezio P, Broggini M. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res 2011; 71:4573 - 84; http://dx.doi.org/10.1158/0008-5472.CAN-10-4322; PMID: 21602434
   PubMed Web of Science ®Google Scholar
• Li T, Wang J, Wang X, Yang N, Chen SM, Tong LJ, Yang CH, Meng LH, Ding J. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant. J Pharmacol Exp Ther 2010; 334:830 - 8; http://dx.doi.org/10.1124/jpet.110.167940; PMID: 20522531
   PubMed Web of Science ®Google Scholar
• Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68:8022 - 30; http://dx.doi.org/10.1158/0008-5472.CAN-08-1385; PMID: 18829560
   PubMed Web of Science ®Google Scholar
• Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4:648 - 57; http://dx.doi.org/10.1038/ncb839; PMID: 12172553
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Phase II Trial of Akt Inhibitor MK2206 in Patients With Advanced Breast Cancer Who Have Tumors With a PIK3CA Mutation, or an AKT Mutation, and/or PTEN Loss/PTEN Mutation. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011- [cited 2014 March 27]. Available from: http://clinicaltrials.gov/ct2/show/NCT01277757 NLM identifier: NCT01277757.
   Google Scholar
• QuantumLeap Healthcare Collaborative. I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009- [cited 2014 March 27]. Available from: http://clinicaltrials.gov/ct2/show/NCT01042379 NLM identifier: NCT01042379.
   Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177 - 82; http://dx.doi.org/10.1126/science.3798106; PMID: 3798106
   PubMed Web of Science ®Google Scholar
• Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118:3065 - 74; PMID: 18725988
   PubMed Web of Science ®Google Scholar
• Carrière A, Cargnello M, Julien LA, Gao H, Bonneil E, Thibault P, Roux PP. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol 2008; 18:1269 - 77; http://dx.doi.org/10.1016/j.cub.2008.07.078; PMID: 18722121
   PubMed Web of Science ®Google Scholar
• Carriere A, Romeo Y, Acosta-Jaquez HA, Moreau J, Bonneil E, Thibault P, Fingar DC, Roux PP. ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 2011; 286:567 - 77; http://dx.doi.org/10.1074/jbc.M110.159046; PMID: 21071439
   PubMed Web of Science ®Google Scholar
• Wheater MJ, Johnson PW, Blaydes JP. The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. Cancer Biol Ther 2010; 10:728 - 35; http://dx.doi.org/10.4161/cbt.10.7.12965; PMID: 20686366
   PubMed Web of Science ®Google Scholar
• Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons S, Ellis KE, et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res 2011; 71:1849 - 57; http://dx.doi.org/10.1158/0008-5472.CAN-10-3298; PMID: 21233335
   PubMed Web of Science ®Google Scholar
• Hvidtfeldt UA, Gunter MJ, Lange T, Chlebowski RT, Lane D, Farhat GN, Freiberg MS, Keiding N, Lee JS, Prentice R, et al. Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption, and breast cancer. Cancer Epidemiol Biomarkers Prev 2012; 21:1203 - 12; http://dx.doi.org/10.1158/1055-9965.EPI-12-0310; PMID: 22564867
   PubMed Web of Science ®Google Scholar
• Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27:3297 - 302; http://dx.doi.org/10.1200/JCO.2009.19.6410; PMID: 19487376
   PubMed Web of Science ®Google Scholar
• Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8:909 - 15; http://dx.doi.org/10.4161/cc.8.6.7933; PMID: 19221498
   PubMed Web of Science ®Google Scholar
• Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 2012; 32:1627 - 37; PMID: 22593441
   PubMed Web of Science ®Google Scholar
• Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 2012; 135:639 - 46; http://dx.doi.org/10.1007/s10549-012-2170-x; PMID: 22847511
   PubMed Web of Science ®Google Scholar
• Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012; 135:821 - 30; http://dx.doi.org/10.1007/s10549-012-2223-1; PMID: 22933030
   PubMed Web of Science ®Google Scholar
• Chen Y, Li S. Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia. Onco Targets Ther 2014; 7:177 - 86; PMID: 24516334
   PubMed Web of Science ®Google Scholar
• Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, Nanda N, Benichou AC, Leonoudakis J, Khoury HJ, et al. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk 2013; 13:584 - 91; http://dx.doi.org/10.1016/j.clml.2013.03.020; PMID: 23787123
   PubMed Web of Science ®Google Scholar